A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.
about
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationHighlights From the American Association of Pharmaceutical Scientists/ International Transporter Consortium Joint Workshop on Drug Transporters in Absorption, Distribution, Metabolism, and Excretion: From the Bench to the Bedside - Clinical PharmacoSandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy.Organic Ion Transporters and Statin Drug Interactions.Role of Hepatic Drug Transporters in Drug Development.
P2860
Q28088352-8A80AE72-0DA1-4B45-9DC8-4B17D40A9174Q33782972-46B991E2-2FC2-44B7-B8A7-1F34160F74BAQ36972804-2CEA4262-9CC9-4614-AB57-B17A95B93EC2Q37279044-DCB6F084-777E-4402-A9A8-902773F4AC90Q38233298-B94C99DC-33B9-40C9-AE77-5817E992748AQ38302225-E181295B-13C0-4215-9238-097962E1F8FEQ38707798-909FD836-248F-44C4-A1FC-E75D7738D1A0Q38798449-7DEB3583-1A9D-4392-B3EB-D8BAAC488D23Q38844656-31977B94-055E-461C-AD2C-65FD5F0B4007Q38855314-9B79E865-BBF8-4FBF-A5C7-C1D7C4483098Q39941536-4431F270-8B26-4454-B837-4EF9427579E0Q41706349-A75330B4-64D7-45F2-A84F-597E00BF8612Q42351660-12F259AD-648D-445E-BCC4-E7A16E4E2B49Q45243894-02A67229-991D-4A47-93EF-69723D5014D5Q46243170-D63FE617-7520-4D58-BF37-474F80DE19AAQ47361769-14050427-7E17-440C-B446-FF0C1FED7633Q51659233-F6F77E9E-2942-495E-94FD-BDA7F887536F
P2860
A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@en
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@nl
type
label
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@en
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@nl
prefLabel
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@en
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@nl
P2093
P2860
P1476
A "middle-out" approach to hum ...... ased pharmacokinetic modeling.
@en
P2093
Angela C Wolford
Avijit Ghosh
Hugh A Barton
Keith A Riccardi
Phillip D Yates
Tristan S Maurer
P2860
P2888
P304
P356
10.1007/S10928-014-9357-1
P577
2014-04-10T00:00:00Z